Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

18.55 +0.78 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Tuesday Markets Coverage
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
Via Talk Markets
Novocure to Participate in Two Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial
Novocure Ltd (NASDAQ: NVCR) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and... 
Via Benzinga
Recap: NovoCure Q3 Earnings
NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 28, 2021 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
What's the Outlook for Novocure?
There's a lot riding on clinical studies of the company's tumor treating fields product. 
Via The Motley Fool
3 Healthcare Stocks That Could Be Turkeys in November
You might want to avoid stuffing your portfolio with them. 
Via The Motley Fool
NovoCure (NVCR) Q3 2021 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
Why NovoCure Stock Is Sinking This Week
Investors weren't happy with the company's Q3 update. 
Via The Motley Fool
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now
Novocure's stock keeps sliding, but the company continues to perform. 
Via The Motley Fool
This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping?
Is it time to buy this stock nearly at its 52 week low? 
Via The Motley Fool
Cramer Likes Ford, But Suggests Waiting For Dips To Buy These Stocks
On Friday's "Mad Money Lightning ... 
Via Benzinga
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
From Novocure
Via Business Wire
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Novocure to Report Third Quarter 2021 Financial Results
From Novocure
Via Business Wire
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating... 
Via Benzinga
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.